AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10671921 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary node sample without radiotherapy
Number of subjects: 466
Study 9611401 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients (European)
Number of subjects: 174
Study 9611401 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with neuropathy (European)
Number of subjects: 174
Study 9611401 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (European)
Number of subjects: 174
Study 9611401 — intervention group
Group type: EXPERIMENTAL
Intervention: North African insulin-dependent diabetic patients
Number of subjects: 174
Study 9611401 — intervention group
Group type: COMPARATOR
Intervention: North African control subjects
Number of subjects: 174
Study 9611401 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of restricted allele in European diabetic individuals
Number of subjects: 174
Study 8406644 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 1 mg/kg body weight on alternate days, starting with 0.05 mg/kg on the first day, total dose of 20 mg/kg
Number of subjects: 150
Study 8406644 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate (SAG) 20 mg/kg body weight, im daily for 30 days
Number of subjects: 150
Study 3534899 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg maprotiline and 9 mg haloperidol per day (for the first six days)
Number of subjects: 28
Study 3534899 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with maprotiline
Number of subjects: 28
Study 31412815 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 1068
Study 31412815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 1068
Study 31412815 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time
Number of subjects: 1068
Study 31412815 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 1068
Study 30220648 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/10 µg
Number of subjects: 2389
Study 30220648 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/10 µg
Number of subjects: 2389
Study 30220648 — intervention group
Group type: COMPARATOR
Intervention: FF MDI
Number of subjects: 2389
Study 26554869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-expectation provider communication
Number of subjects: 0
Study 26554869 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 0
Study 26554869 — intervention group
Group type: COMPARATOR
Intervention: High expectation vs Neutral expectation
Number of subjects: 0
Study 25344737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotation tank treatment
Number of subjects: 65
Study 25344737 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study 22733065 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous oseltamivir
Number of subjects: 0
Study 22733065 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous oseltamivir
Number of subjects: 0
Study 22733065 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg intravenous oseltamivir
Number of subjects: 0
Study 22733065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study 20815736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir started within 12 hours of symptom onset
Number of subjects: 408
Study 20815736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir started within 24 hours of symptom onset
Number of subjects: 408
Study 20815736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir started within 24 hours of symptom onset in unvaccinated children
Number of subjects: 408
Study 20815736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 17218362 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 250 mg, 3 doses, 8 hours apart
Number of subjects: 6
Study 17218362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15897554 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine treatment
Number of subjects: 191
Study 15897554 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 191
Study 12232483 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with total mesorectal excision for T1/2 N0 rectal cancers
Number of subjects: 0
Study 12232483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy
Number of subjects: 0
Study 12232483 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term pre-operative radiotherapy
Number of subjects: 0
Study 12232483 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term neoadjuvant radiochemotherapy
Number of subjects: 0
Study 12232483 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 0
Study 12232483 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional radiochemotherapy
Number of subjects: 0
Study 9534112 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cooperative learning programme
Number of subjects: 24
Study 9534112 — intervention group
Group type: COMPARATOR
Intervention: Control classrooms
Number of subjects: 24
Study 7663010 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of intercellular adhesion molecule-1 at diagnosis in Hodgkin's disease patients
Number of subjects: 104
Study 7663010 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of intercellular adhesion molecule-1 in complete remission
Number of subjects: 104
Study 7663010 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of intercellular adhesion molecule-1 in patients with advanced disease who attained complete remission
Number of subjects: 104
Study 7663010 — intervention group
Group type: COMPARATOR
Intervention: Serum levels of intercellular adhesion molecule-1 in patients who failed to attain complete remission
Number of subjects: 104
Study 7663010 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum levels of intercellular adhesion molecule-1 with clinical features
Number of subjects: 104
Study 2503895 — intervention group
Group type: EXPERIMENTAL
Intervention: Daonil (Hoechst)
Number of subjects: 18
Study 2503895 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomin (Lennon)
Number of subjects: 18
Study 2503895 — intervention group
Group type: COMPARATOR
Intervention: Melix (Lagamed)
Number of subjects: 18
Study 782976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine A (with galactose)
Number of subjects: 173
Study 782976 — intervention group
Group type: COMPARATOR
Intervention: Vaccine B (without galactose)
Number of subjects: 173
Study 30871801 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 10
Study 26848182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sulfate (oral)
Number of subjects: 72
Study 26848182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (intravenous)
Number of subjects: 72
Study 26848182 — intervention group
Group type: COMPARATOR
Intervention: Control (non-inflamed subjects)
Number of subjects: 72
Study 25096309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day oral glucosamine sulphate
Number of subjects: 70
Study 25096309 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program for 6 months
Number of subjects: 70
Study 23820157 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 259
Study 23820157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 259
Study 21401690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical context (short stem suggestive of cardiac valvular diagnoses)
Number of subjects: 159
Study 21401690 — intervention group
Group type: COMPARATOR
Intervention: No clinical history
Number of subjects: 159
Study 17511191 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (for women)
Number of subjects: 120
Study 17511191 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (for men)
Number of subjects: 120
Study 15863491 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 52
Study 15863491 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 52
Study 12220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10
Study 12220941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 10
Study 10463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (235 mg/day)
Number of subjects: 107
Study 10463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (77 mg/day)
Number of subjects: 107
Study 10463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 107
Study 10463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 107
Study 7886982 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 152
Study 7886982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 2791174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5%
Number of subjects: 12
Study 2791174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.375%
Number of subjects: 12
Study 2791174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.25%
Number of subjects: 12
Study 698167 — intervention group
Group type: EXPERIMENTAL
Intervention: Small intakes of alcohol
Number of subjects: 10
Study 698167 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic meal of food plus alcohol
Number of subjects: 10
Study 698167 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic meal of food
Number of subjects: 10
Study 31274485 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg at induction of anesthesia)
Number of subjects: 56
Study 31274485 — intervention group
Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 56
Study 27984188 — intervention group
Group type: EXPERIMENTAL
Intervention: 579 kJ (138 kcal) liquid meal
Number of subjects: 10
Study 27984188 — intervention group
Group type: EXPERIMENTAL
Intervention: 828 kJ (198 kcal) liquid meal
Number of subjects: 10
Study 27984188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1776 kJ (424 kcal) liquid meal
Number of subjects: 10
Study 27984188 — intervention group
Group type: EXPERIMENTAL
Intervention: 4188 kJ (1001 kcal) liquid meal
Number of subjects: 10
Study 27984188 — intervention group
Group type: COMPARATOR
Intervention: High-energy meals
Number of subjects: 10
Study 24916954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity manikin simulator
Number of subjects: 0
Study 24916954 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity manikin simulator
Number of subjects: 0
Study 23176897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 294
Study 23176897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 21486552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sankang Capsule
Number of subjects: 543
Study 21486552 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola Rosea Capsule
Number of subjects: 543
Study 21486552 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Pollen Capsule
Number of subjects: 543
Study 21486552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study 19271173 — intervention group
Group type: EXPERIMENTAL
Intervention: Yixuesheng capsule (YXS) combined with recombination human erythropoietin (RHE)
Number of subjects: 65
Study 19271173 — intervention group
Group type: COMPARATOR
Intervention: Recombination human erythropoietin (RHE) alone
Number of subjects: 65
Study 16982228 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (EE 20 microg/day and norelgestromin 150 microg/day)
Number of subjects: 24
Study 16982228 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (EE 35 microg and norgestimate 250 microg)
Number of subjects: 24
Study 15208650 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (1000 mg/day during conditioning)
Number of subjects: 60
Study 15208650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 60
Study 12463322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild asphyxia group
Number of subjects: 31
Study 12463322 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate asphyxia group
Number of subjects: 31
Study 12463322 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 9865704 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0
Study 9865704 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study 7631644 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg cocaine
Number of subjects: 12
Study 7631644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1696671 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 19
Study 1696671 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 19
Study 1696671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Digoxin and Quinapril
Number of subjects: 19
Study 375687 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 36
Study 375687 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 36
Study 30946757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing Bifidobacterium lactis CNCM I‐2494 (FMP)
Number of subjects: 125
Study 30946757 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 125
Study 27889307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 15 mg/kg (Group B)
Number of subjects: 180
Study 27889307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 10 mg/kg (Group C)
Number of subjects: 180
Study 27889307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 30 mg/kg (Group A)
Number of subjects: 180
Study 27889307 — intervention group
Group type: COMPARATOR
Intervention: No Tranexamic Acid (Group D)
Number of subjects: 180
Study 25894177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose in water plus insulin infusion (group 1)
Number of subjects: 120
Study 25894177 — intervention group
Group type: COMPARATOR
Intervention: Dextrose in water infusion (group 2)
Number of subjects: 120
Study 24113621 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective axillary dissection (SAD)
Number of subjects: 60
Study 24113621 — intervention group
Group type: COMPARATOR
Intervention: Complete axillary lymph node dissection (ALND)
Number of subjects: 60
Study 21248295 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead exposure
Number of subjects: 3941
Study 21248295 — intervention group
Group type: COMPARATOR
Intervention: Creatinine-based MDRD and CKD-EPI equations
Number of subjects: 3941
Study 19170462 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional behavioral couple therapy
Number of subjects: 0
Study 19170462 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative behavioral couple therapy
Number of subjects: 0
Study 19170462 — intervention group
Group type: EXPERIMENTAL
Intervention: Less distressed couples
Number of subjects: 0
Study 19170462 — intervention group
Group type: COMPARATOR
Intervention: Moderation analyses
Number of subjects: 0
Study 17588810 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) treatment for one month
Number of subjects: 14
Study 15572757 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 5213
Study 15572757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5213
Study 11488550 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 0
Study 11488550 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 9692434 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic technique (group A, n = 54)
Number of subjects: 112
Study 9692434 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (group B, n = 58)
Number of subjects: 112
Study 7843574 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation letter providing treatment recommendations
Number of subjects: 73
Study 7843574 — intervention group
Group type: COMPARATOR
Intervention: Control physicians (no psychiatric consultation letter)
Number of subjects: 73
Study 3048533 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 45
Study 3048533 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium tetradecyl sulphate (STD)
Number of subjects: 45
Study 30740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm swing exercise (ASE) training for 3 months, 30 minutes/day, 3 days/week
Number of subjects: 50
Study 30740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm swing exercise (ASE) training
Number of subjects: 50
Study 30740133 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained daily routine activities without regular exercise)
Number of subjects: 50
Study 28431800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 28431800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29106100 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2 50/50 mixture
Number of subjects: 147
Study 29106100 — intervention group
Group type: COMPARATOR
Intervention: 50% oxygen in air (placebo)
Number of subjects: 147
Study 24990423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 kcal/mL enteral nutrition solution
Number of subjects: 112
Study 24990423 — intervention group
Group type: COMPARATOR
Intervention: 1.0 kcal/mL enteral nutrition solution
Number of subjects: 112
Study 22798383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 1.10 mL/kg for men and women
Number of subjects: 207
Study 22798383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: men 1.10 mL/kg, women 0.99 mL/kg
Number of subjects: 207
Study 22798383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 207
Study 20558286 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural kale extract
Number of subjects: 22
Study 20558286 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 22
Study 17506931 — intervention group
Group type: COMPARATOR
Intervention: Soya nut diet
Number of subjects: 42
Study 17506931 — intervention group
Group type: COMPARATOR
Intervention: Soya protein diet
Number of subjects: 42
Study 17506931 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet (DASH diet)
Number of subjects: 42
Study 15734772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held steel paddle electrodes
Number of subjects: 201
Study 15734772 — intervention group
Group type: COMPARATOR
Intervention: Adhesive patch electrodes
Number of subjects: 201
Study 15734772 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 201
Study 15734772 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 201
Study 15734772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over from monophasic to biphasic shock
Number of subjects: 201
Study 15734772 — intervention group
Group type: COMPARATOR
Intervention: Patch electrodes after cross-over
Number of subjects: 201
Study 12390611 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous dipyrone
Number of subjects: 74
Study 12390611 — intervention group
Group type: COMPARATOR
Intervention: 10 mL 0.9% physiological saline (placebo)
Number of subjects: 74
Study 10458683 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical treatment
Number of subjects: 451
Study 10458683 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 451
Study 8928632 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 40 dB HL
Number of subjects: 6
Study 8928632 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 50 dB HL
Number of subjects: 6
Study 8928632 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 60 dB HL
Number of subjects: 6
Study 8928632 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 65 dB HL
Number of subjects: 6
Study 2214124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine (0.4 mg.kg‐1)
Number of subjects: 30
Study 2214124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ranitidine (0.1 mg.kg‐1)
Number of subjects: 30
Study 2214124 — intervention group
Group type: COMPARATOR
Intervention: Apple juice (control group)
Number of subjects: 30
Study 656293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 35
Study 656293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 35
Study 656293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and Prednisolone
Number of subjects: 35
Study 31351121 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching and disease-management services
Number of subjects: 0
Study 31351121 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 28072611 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Shampoo
Number of subjects: 42
Study 28072611 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine (PI)
Number of subjects: 42
Study 28072611 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl Alcohol (IA)
Number of subjects: 42
Study 26547662 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of sulfonylureas
Number of subjects: 443
Study 26547662 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of metformin
Number of subjects: 443
Study 26547662 — intervention group
Group type: EXPERIMENTAL
Intervention: Past use of sulfonylureas
Number of subjects: 443
Study 26547662 — intervention group
Group type: EXPERIMENTAL
Intervention: Past use of metformin
Number of subjects: 443